News

Regeneron's weight-loss drug combo helps preserve muscle in study
Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...
Regeneron says its weight-loss drug helped preserve muscle mass in study
Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...
Ozempic Without Muscle Loss? New Drug Combo Trial Finds It’s Possible
By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...
PharmExec10d
Regeneron’s Semaglutide Plus Trevogrumab Combo Demonstrates Superior Fat Loss with Reduced Muscle Wasting in Obesity Trial
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...
NextBigFuture9d
FINALLY Miracle Combo – Weight Loss and Muscle Growth Without Steroids
A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...
Fierce Biotech12d
Regeneron pens $2B pact for Hansoh's potential obesity rival to Lilly's Zepbound
Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...
Regeneron Pharmaceuticals, Inc. (REGN)’s Weight-Loss Drug Aids Muscle Preservation in Wegovy Users
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Monday that its experimental drug, when combined with Novo ...
PMLive10d
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...
Regeneron reports early data in mid-stage trial of obesity treatment
Regeneron’s trial shows semaglutide combos improve fat loss while preserving muscle in obesity treatment. Read more here.
Nasdaq12d
Regeneron Reports Interim Data From Phase 2 COURAGE Study
(RTTNews) - Regeneron Pharmaceuticals ... for the treatment of obesity. COURAGE study was designed to investigate the quality of weight loss in patients with obesity. The treatment is divided ...